False-Negative and False-Positive Results in FDG-PET and PET/CT in Breast Cancer

PET Clinics

Volumn 4, Issue 3, 2009, Pages 289-298

  Kumar, Rakesh ^a   Rani, Neerja ^a   Patel, Chetan ^a   Basu, Sandip ^b   Alavi, Abass ^c  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b BHABHA ATOMIC RESEARCH CENTRE   (India)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Breast cancer; Diagnosis; False negative; False positive; PET CT; Tumors

Indexed keywords

3' FLUOROTHYMIDINE F 18; BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; KI 67 ANTIGEN;

AXILLARY LYMPH NODE; BONE METASTASIS; BREAST AUGMENTATION; BREAST BIOPSY; BREAST CANCER; BREAST LESION; BREAST RECONSTRUCTION; BREATHING MECHANICS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER MORPHOLOGY; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE TRANSPORT; HUMAN; INFLAMMATION; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTITIS; NONHUMAN; PATIENT POSITIONING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME;

EID: 70449698366     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2009.09.002     Document Type: Review

References (56)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 59 (2009) 225-249
2. Jemal A., Clegg L.X., Elizabeth Ward E., et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101 1 (2004) 3-27
3. Wahl R.L., Cody R.L., Hutchins G.D., et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 179 (1991) 765-770
4. Adler L.P., Crowe J.P., al-Kaisi N.K., et al. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 187 (1993) 743-750
5. Kumar R., Chauhan A., Zhuang H., et al. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 98 3 (2006) 267-274
6. Avril N., Rose C.A., Schelling M., et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18 (2000) 3495-3502
7. Kumar R., Loving V., Chauhan A., et al. Dual time point imaging and its potential to improve breast cancer diagnosis with F18-Fluorodeoxyglucose positron emission tomography. J Nucl Med 46 11 (2005) 1819-1824
8. Heusner T.A., Kuemmel S., Umutlu L., et al. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 49 8 (2008) 1215-1222
9. 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 42 (2001) 9-16
10. Buck A., Schirrmeister H., Kuhn T., et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 29 (2002) 1317-1323
11. Bos R., van Der Hoeven J.J., van Der Wall E., et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20 (2002) 379-387
12. Buck A.K., Schirrmeister H., Mattfeldt T., et al. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 31 suppl 1 (2004) S80-S87
13. Avril N., Bense S., Ziegler S.I., et al. Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med 38 (1997) 1186-1191
14. Torizuka T., Zasadny K.R., Recker B., et al. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology 207 (1998) 767-774
15. 18F] fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 25 (1998) 1429-1434
16. Schirrmeister H., Kuhn T., Guhlmann A., et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 28 (2001) 351-358
17. Barnard N.J., Hall P.A., Lemoine N.R., et al. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol 152 (1987) 287-295
18. Kubota R., Yamada S., Kubota K., et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissue studied by microautoradiography. J Nucl Med 33 (1992) 1972-1980
19. Brown R.S., Leung J.Y., Fisher S.J., et al. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma. I. Are inflammatory cells important?. J Nucl Med 36 (1995) 1854-1861
20. Vranjesevic D., Schiepers C., Silverman D.H., et al. Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med 44 (2003) 1238-1242
21. 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med 45 (2004) 1423-1424
22. Kumar R., Chauhan A., Zhuang H., et al. Standardized uptake value in normal breast: effect of age, density and menopausal status. Mol Imaging Biol 8 6 (2006) 355-362
23. Knuuti J., Nuutila P., Ruotsalainen U., et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med 33 (1992) 1255-1262
24. Langen K.J., Braun U., Kops E.R., et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 34 (1993) 355-359
25. Wahl R.L., Henry C.A., and Ethier S.P. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-l8]-fluoro-2-deoxy-D-glucose FDG in rodents with mammary carcinoma. Radiology 183 (1992) 643-647
26. Hoffmann E.J., Huang S., and Phelps M.E. Quantitation in positron emission computed tomography: effect of object size. J Comput Assist Tomogr 3 (1979) 299-308
27. Nemoto T., Vana J., Bedwani R.N., et al. Management and survival of female breast cancer: results of a national survey by American College of Surgeons. Cancer 45 (1980) 2917-2924
28. Albertini J.J., Lyman G.H., Cox C., et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 276 (1996) 1818-1822
29. Kumar R., Jana S., Heiba S.I., et al. Retrospective analysis of sentinel node localization in multicentric palpable and non-palpable breast cance. J Nucl Med 44 (2003) 7-10
30. Kumar R., Zhuang H., Schnall M., et al. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer. Nucl Med Commun 27 (2006) 231-236
31. Utech C.I., Young C.S., and Winter P.F. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 23 (1996) 1588-1593
32. van der Hoeven J.J., Hoekstra O.S., Comans E.F., et al. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 236 (2002) 619-624
33. Lovrics P.J., Chen V., Coates G., et al. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 11 (2004) 846-853
34. Cook G.J., Houston S., Rubens R., et al. Detection of bone metastases in breast cancer by 18-FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16 (1998) 3375-3379
35. Boerman O.C., Storm G., Oyen W.J., et al. Sterically stabilized liposomes labeled with indium-111 to image focal infection. J Nucl Med 36 (1995) 1639-1644
36. Yamada S., Kubota K., Kubota R., et al. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 36 (1995) 1301-1306
37. 18F-FDG uptake in experimental soft-tissue abscesses in rats. Radiology 223 (2002) 446-451
38. Lim H.S., Yoon W., Chung T.W., et al. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitation. Radiographics 27 Suppl 1 (2007) S197-S213
39. Ramtahalsing R., Arens A.I., Vliegen R.F., et al. False positive 18F-FDG PET/CT due to gynecomastia. Eur J Nucl Med Mol Imaging 34 4 (2007) 614
40. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer (2009) [Epub ahead of print]
41. Das C.J., Kumar R., Balakrishnan V.B., et al. Disseminated tuberculosis masquerading metastatic breast carcinoma in PET-CT scan. Clin Nucl Med 33 5 (2008) 359-361
42. Bakheet S.M., Powe J., Ezzat A., et al. F-18-FDG uptake in tuberculosis. Clin Nucl Med 23 11 (1998) 739-742
43. Bakheet S.M., Powe J., Kandil A., et al. F-18 FDG uptake in breast infection and inflammation. Clin Nucl Med 25 2 (2000) 100-103
44. 18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits. J Nucl Med 47 (2006) 1351-1358
45. 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 45 (2004) 695-700
46. 18F-galacto-RGD in cancer patients. J Nucl Med 46 (2005) 1333-1341
47. Krupitskaya Y., Eslamy H.K., Nguyen D.D., et al. Osteoblastic bone flare on F18-FDG PET in nonsmall cell lung cancer (NSCLC)patients receiving bevacizumab in addition to standard chemotherapy. J Thorac Oncol 4 3 (2009) 429-431
48. Kobe K., Chin T., Aoki R., et al. A false-positive fluorodeoxyglucose positron emission tomography (FDG-PET) imaging result for a patient after augmentation mammoplasty. Aesthetic Plast Surg 33 4 (2009) 611-615
49. Bhargava P., Glass E., and Ghesani M. Inflammatory F-18 FDG uptakes secondary to ruptured breast prosthesis. Clin Nucl Med 31 4 (2006) 227-228
50. Hurwitz R. F-18 FDG positron emission tomographic imaging in a case of ruptured breast implant: inflammation or recurrent tumor?. Clin Nucl Med 28 9 (2003) 755-756
51. Wahl R.L., Helvie M.A., Chang A.E., et al. Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose-PET. J Nucl Med 35 5 (1994) 872-875
52. Chen C.J., Lee B.F., Yao W.J., et al. A false positive F-FDG PET/CT scan caused by breast silicone injection. Korean J Radiol 10 2 (2009) 194-196
53. Binns D, Hicks RJ. Pattern of F-18 FDG uptake and excretion in the lactating breast [abstract]. Proceedings of the 9th International PET Conference, San Diego (CA). 1997.
54. Yasuda S., Fujii H., Takahashi W., et al. Lactating breast exhibiting high F-18 FDG uptake. Clin Nucl Med 23 (1998) 767-768
55. Hicks R.J., Binns D., and Stabin M.G. Pattern of uptake and excretion of (18)F-FDG in the lactating breast. J Nucl Med 42 8 (2001) 1238-1242
56. Bakheet S.M., and Hammami M.M. Patterns of radioiodine uptake by the lactating breast. Eur J Nucl Med 21 (1994) 604-608